Similarly, demonstrated encapsulated cGAMP and CpG ODN plus the model antigen OVA an induction of a boosted Th1 immune response in vitro, decreased M2 macrophages, and reduced tumor volume of up to 70% in melanoma in vivo.[108] The use of a bridging‐lipid nanoparticle targeting CD47/PD‐1 on tumor‐associated myeloid cells in glioblastoma, combined with diABZI, reprogrammed these cells from an immunosuppressive into an anti‐tumoral state.[109] Furthermore, Nakamura et al. The gene discussed is CD47; the disease is glioblastoma.